SCHEMBL21519372

SCHEMBL21519372

Cc1cc(=O)nc(N/N=C/c2c(Cl)ccc(Cl)c2Cl)[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.46
▸ MAPT P10636 9/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ LMNA P02545 3/20 0.43
▸ ALDH1A1 P00352 10/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ GAA P10253 5/20 0.40
▸ ALPL P05186 1/20 0.40
▸ ALPI P09923 1/20 0.40
▸ ALPG P10696 1/20 0.40
▸ POLB P06746 2/20 0.39
▸ KDM4E B2RXH2 4/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ PSMD14 O00487 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ HPGD P15428 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21519374 1.00 KMT2A (0.46) KMT2AMAPTRXFP1LMNAALDH1A1
SCHEMBL21519445 0.89 KMT2A (0.52) KMT2AMAPTRXFP1LMNAALDH1A1
SCHEMBL21519447 0.89 KMT2A (0.52) KMT2AMAPTRXFP1LMNAALDH1A1
SCHEMBL21519609 0.83 KMT2A (0.53) KMT2AMAPTRXFP1LMNAALDH1A1
SCHEMBL21519607 0.83 KMT2A (0.53) KMT2AMAPTRXFP1LMNAALDH1A1
SCHEMBL21519665 0.83 KMT2A (0.58) KMT2AMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL21519664 0.83 KMT2A (0.58) KMT2AMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL21519616 0.82 MAPT (0.53) KMT2AMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL21519620 0.82 MAPT (0.53) KMT2AMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL21519669 0.80 KMT2A (0.43) KMT2AMAPTRXFP1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12006294-B2 Therapeutic compounds REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2024-06-11 — — US disclosed
US-20190330157-A1 THERAPEUTIC COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA 2019-10-31 — — US disclosed
US-20190330157-A1 THERAPEUTIC COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA 2019-10-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190330157-A1 THERAPEUTIC COMPOUNDS OPRL1, INA, OGFR KMT2A 3083/4885MAPT 3826/4885RXFP1 25/4885
US-12006294-B2 Therapeutic compounds OPRL1, INA, OGFR KMT2A 3083/4885MAPT 3826/4885RXFP1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback